(8)

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) An 8-oxoadenine compound represented by the following formula (1):

, wherein A is a group selected from the group consisting of the following formulas (2) to (8):

, wherein R² is <u>a</u> hydrogen atom, <u>or</u> an alkyl group;

R³ is <u>a hydrogen</u> atom or an alkyl group;

R is a halogen atom, a haloalkyl group, a haloalkoxy group, an alkyl group, an alkoxy group, amino group, an alkylamino group or a dialkylamino group;

n is an integer of 0 to 2, and when n is 2, R_S may be the same or different;

X¹ is <u>an</u> oxygen atom, <u>a</u> sulfur atom, SO₂, NR⁴ (wherein R⁴ is <u>a</u> hydrogen atom or an alkyl group), or a single bond;

Z is a straight or branched chain alkylene;

R¹ is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) The 8-oxoadenine compound according to claim 1, wherein R^2 is a substituted or unsubstituted $C_{1.8}$ alkyl group, wherein said-alkyl-group may be substituted by one or plural substituents which may be the same or different, and the substituents (I) on said alkyl group are selected from the group consisting of a halogen atom, hydroxy group, carboxy group, $C_{3.8}$ cycloalkyl-group, a $C_{1.6}$ alkoxy group, a $C_{1.6}$ alkylsulfonyl-group, a $C_{1.6}$ alkylsulfonyl-group, a cubstituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted 6 to 10 membered aryl group, a substituted or unsubstituted 5-to-10 membered heteroaryl group which contains 1 to 4 hetero atoms consisting of 0 to 2 nitrogen atoms, 0 to 1 exygen atom and 0 to 1 sulfur atom, and a substituted or unsubstituted 4 to 7 membered saturated heterocyclic group which contains 1 to 4 hetero atoms consisting of 0 to 2 nitrogen atoms, 0 to 2 oxygen atoms and 0 to 2 sulfur atoms;

R³ is a hydrogen atom or an alkyl group;

R is a halogen atom, a C_{1-6} haloalkyl group, a C_{1-6} haloalkoxy group, a C_{1-6} alkyl group, a C_{1-6} alkoxy group, an amino group, an C_{1-6} alkylamino group, or a di C_{1-6} alkyl amino group; n is an integer of 0 to 2, and when n is 2, Rs may be the same or different;

 X^1 is <u>an</u> oxygen atom, <u>a</u> sulfur atom, SO_2 , NR^4 (wherein R^4 is <u>a</u> hydrogen atom or a C_{1-6} alkyl group), or a single bond;

Z is a straight or branched chain C_{1-8} alkylene;

R¹ is a substituted or unsubstituted alkyl group and the substituents (II) of the said alkyl group, are selected from the group consisting of a halogen atom, a hydroxy group, a C₁-4 alkoxy group, a C₁-4 alkylthio group, a C₁-4 alkylsulfonyl group, a C₂-5 alkoxycarbonyl group, an amino group, a C₁-4 alkyl amino group, di-C₁-4 alkyl amino group, a morpholino group, a 1-piperadinyl group, a 1-pyrrolidinyl group, a carbamoyl group, a substituted or unsubstituted or unsubstituted or unsubstituted aryloxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted 5 to 10 membered heteroaryl group which contains 1 to 4 heteroatoms selected from 0 to 2 nitrogen atoms, 0 to 1 oxygen atom and 0 to 1 sulfur atom, or a substituted or unsubstituted C₃-3 cycloalkoxy group, the substituents (IV) of said aryl group, heteroaryl group, and cycloalkyl group, are selected from the group consisting of a halogen atom, a hydroxy group, a C₁-6 alkyl group, a C₁-6 alkoxy group, a C₁-6 haloalkyl group, a C₁-6 haloalkoxy group, and an amino group, a C₁-6 alkyl amino group, in the formula (1), or its pharmaceutically acceptable salt.

- 3. (Currently amended) The 8-oxoadenine compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R² in the formula (1) is <u>a methyl group</u>.
- 4. 5. (Canceled)
- 6. (Currently amended) The 8-oxoadenine compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R³ in the formula (1) is <u>a hydrogen</u> atom.
- 7. (Previously Presented) The 8-oxoadenine compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z in the formula (1) is a straight chain C₁₋₅ alkylene group.

- 8. (Previously Presented) The 8-oxoadenine compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein X¹ in the formula (1) is a single bond, oxygen atom or sulfur atom.
- 9. (Currently Amended) The 8-oxoadenine compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 in the formula (1) is a C_{1-6} alkyl group which is optionally substituted by an alkoxycarbonyl group, a hydroxy group or an alkoxy group.
- 10. (Currently Amended) The 8-oxoadenine compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein X^{I} in the formula (1) is a single bond, R^{I} is a C_{I-6} alkyl group which is substituted by a methoxycarbonyl group.
- 11. (Previously presented) A pharmaceutical composition comprising the 8-oxoadenine compound or a pharmaceutically acceptable salt thereof as claimed in claim 1 as an active ingredient and an acceptable carrier.

12. - 14. (Canceled)

15. - 19. (Canceled)

20. (Currently Amended) A process for preparing the 8-oxoadenine compound as claimed in claim 1, which comprises brominating a compound represented by the formula (9):

$$R^{1} - X^{1} = X^{1} - X^{1$$

, wherein A is a group selected from the group consisting of the following formulas (2) to (8):

, wherein R^2 is <u>a hydrogen</u> atom, or a substituted or unsubstituted alkyl group; R^3 is <u>a hydrogen</u> atom or an alkyl group;

R is a halogen atom, a haloalkyl group, a haloalkoxy group, an alkyl group, an alkoxy group, amino group, an alkylamino group or a dialkylamino group;

n is an integer of 0 to 2, and when n is 2, R_S may be the same or different;

 X^{I} is <u>an</u> oxygen atom, <u>a</u> sulfur atom, SO_2 , NR^4 (wherein R^4 is <u>a</u> hydrogen atom or an alkyl group), or a single bond;

Z is a straight or branched chain alkylene;

R¹ is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted cycloalkyl group, and hydrolyzing the resultant or reacting the resultant with a metal alkoxide and then hydrolyzing.

21. (Currently Amended) A compound represented by the formula (9):

$$R^{1} \xrightarrow{N} X^{1} X^{1} X^{1} \xrightarrow{N} X^{1} X^{1} \xrightarrow{N} X^{1} X^{1} X^{1} \xrightarrow{N} X^{1} X^{1}$$

, wherein A is a group selected from the group consisting of the following formulas (2) to (8):

$$R^3$$
 $COOR^2$
 $(R)_n$

, wherein R^2 is \underline{a} hydrogen atom, or a substituted or unsubstituted alkyl group; $R^3 \text{ is } \underline{a} \text{ hydrogen atom or an alkyl group;}$

R is a halogen atom, a haloalkyl group, a haloalkoxy group, an alkyl group, an alkoxy group, amino group, an alkylamino group or <u>a</u> dialkylamino group;

n is an integer of 0 to 2, and when n is 2, R_S may be the same or different;

X¹ is <u>an</u> oxygen atom, <u>a</u> sulfur atom, SO₂, NR⁴ (wherein R⁴ is <u>a</u> hydrogen atom or an alkyl group), or a single bond;

Z is a straight or branched chain alkylene;

R¹ is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted cycloalkyl group, or its pharmaceutically acceptable salt.

- 22. (Currently Amended) An 8-oxoadenine compound or its pharmaceutically acceptable salt selected from the group consisting of the following compounds:
- 8-hydroxy-2-(3-hydroxypropylthio)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-2-(4-hydroxybutylthio)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-2-(2-methoxyethylthio)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-2-(3-hydroxypropoxy)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-2-(2-hydroxyethoxy)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-2-(4-hydroxybutoxy)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)-2-(4,4,4-trifluorobutoxy)adenine,
- 8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)-2-[N-(2-methoxyethyl)amino]adenine,
- 2-butoxy-8-hydroxy-9-[2-(3-methoxycarbonylmethylphenyl)ethyl]adenine,
- $2\hbox{-butoxy-8-hydroxy-9-[3-(3-methoxy carbonyl methyl phenyl) propyl]} adenine,$
- $2\hbox{-}(2,3\hbox{-}dihydroxy-1\hbox{-}propoxy)-8\hbox{-}hydroxy-9\hbox{-}(3\hbox{-}methoxycarbonylmethylbenzyl)} adenine,$
- 2-(2-ethoxyethoxy)-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 2-cyclohexylmethoxy-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 2-benzyloxy-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 8-hydroxy-2-(2-methoxycarbonylethyl)-9-(3-methoxycarbonylmethylbenzyl)adenine,
- 2-butoxy-8-hydroxy-9-{(5-methoxycarbonylmethyl-2-thienyl)methyl}adenine,
- 2-butoxy-8-hydroxy-9-{(2-methoxycarbonylmethyl-4-pyridyl)methyl}adenine,
- 2-butoxy-8-hydroxy-9-{(6-methoxycarbonylmethyl-2-pyridyl)methyl}adenine,

- 2-butoxy-8-hydroxy-9-{(4-methoxycarbonylmethyl-2-pyridyl)methyl}adenine,
- 2-butoxy-8-hydroxy-9-[(2-methoxy-5-methoxycarbonylmethyl)benzyl]adenine,
- 2-butoxy-9-[(4-fluoro-3-methoxycarbonylmethyl)benzyl]-8-hydroxyadenine, and
- 2-butoxy-8-hydroxy-9-[(4-methoxy-3-methoxycarbonylmethyl)benzyl]adenine_5
- 9-(3-carboxymethylbenzyl)-8-hydroxy-2-(3-hydroxypropylthio)adenine,
- 9-(3-carboxymethylbenzyl)-8-hydroxy-2-(4-hydroxybutylthio)adenine;
- 9-(3-carboxymethylbenzyl)-8-hydroxy-2-(2-methoxyethylthio)adenine,
- 9-(3-carboxymethylbenzyl) 8-hydroxy-2-(3-hydroxypropoxy)adenine,
- 9-(3-carboxymethylbenzyl)-8-hydroxy-2-(2-hydroxyethoxy)adenine,
- 9-(3-carboxymethylbenzyl)-8-hydroxy-2-(4-hydroxybutoxy)adenine,
- 9-(3-carboxymethylbenzyl) 8-hydroxy-2-(4,4,4-trifluorobutoxy)adenine,
- 9-(3-carboxymethylbenzyl)-8-hydroxy-2-[N-(2-methoxyethyl)amino]adenine,
- 2-butoxy-9-[2-(3-carboxymethylphenyl)ethyl]-8-hydroxyadenine,
- 2-butoxy-9-[3-(3-carboxymethylphenyl)propyl]-8-hydroxyadenine;
- 9-(3-carboxymethylbenzyl)-2-(2,3-dihydroxy-1-propoxy)-8-hydroxyadenine,
- 9-(3-carboxymethylbenzyl)-2-(2-ethoxyethoxy)-8-hydroxyadenine,
- 9-(3-carboxymethylbenzyl)-2-cyclohexylmethoxy-8-hydroxyadenine;
- 2-benzyloxy-9-(3-carboxymethylbenzyl)-8-hydroxyadenine,
- 2-(2-carboxyethyl)-9-(3-carboxymethylbenzyl)-8-hydroxyadenine,
- 2-butoxy 9-{(5-carboxymethyl-2-thienyl)methyl}-8-hydroxyadenine,
- 2-butoxy-9-{(6-carboxymethyl-2-pyridyl)methyl}-8-hydroxyadenine,
- 2-butoxy-9-{(4-carboxymethyl-2-pyridyl)methyl}-8-hydroxyadenine,
- 2-butoxy-9-(5-carboxymethyl-2-methoxy)benzyl-8-hydroxyadenine,
- 2-butoxy-9-(3-carboxymethyl-4-fluoro)benzyl-8-hydroxyadenine, and
- 2-butoxy-9-(3-carboxymethyl-4-methoxy)benzyl-8-hydroxyadenine.